1. Home
  2. FRPH vs AKBA Comparison

FRPH vs AKBA Comparison

Compare FRPH & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo FRP Holdings Inc.

FRPH

FRP Holdings Inc.

HOLD

Current Price

$21.60

Market Cap

435.3M

Sector

Finance

ML Signal

HOLD

Logo Akebia Therapeutics Inc.

AKBA

Akebia Therapeutics Inc.

HOLD

Current Price

$1.35

Market Cap

380.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FRPH
AKBA
Founded
1986
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
435.3M
380.4M
IPO Year
1995
2014

Fundamental Metrics

Financial Performance
Metric
FRPH
AKBA
Price
$21.60
$1.35
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$5.75
AVG Volume (30 Days)
64.4K
2.5M
Earning Date
05-11-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
93.94
EPS
0.16
N/A
Revenue
$41,774,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$135.88
N/A
Revenue Growth
0.65
N/A
52 Week Low
$20.53
$1.14
52 Week High
$29.68
$4.08

Technical Indicators

Market Signals
Indicator
FRPH
AKBA
Relative Strength Index (RSI) 40.83 45.88
Support Level N/A $1.30
Resistance Level $24.59 $1.55
Average True Range (ATR) 0.73 0.07
MACD -0.07 -0.00
Stochastic Oscillator 37.14 6.25

Price Performance

Historical Comparison
FRPH
AKBA

About FRPH FRP Holdings Inc.

FRP Holdings Inc is a holding company engaged in various real estate businesses. The company's business segments are Leasing and management of commercial properties owned by the company (the Industrial/Commercial Segment); Leasing and management of mining royalty land owned by the company (the Mining Royalty Lands Segment); real property acquisition, entitlement, development and construction for apartment, retail, warehouse, and office buildings either alone or through joint ventures (the Development Segment); ownership, leasing and management of buildings through joint ventures (the Multifamily Segment).

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.

Share on Social Networks: